EMA simplifies access to reduced fees for orphan drugs
This article was originally published in SRA
Executive Summary
Sponsors of medicines with an orphan designation in the EU no longer have to pre-notify the European Medicines Agency of their intention to submit a regulatory application in order to be eligible for a fee reduction1.